Business
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference
Following Guidance from the European Medicines Agency’s (EMA) Scientific Advice Working Party (SAWP) Regarding Iopofosine I 131 for the Treatment of Waldenstrom’s Macroglobulinemia (WM), Expects to Submit for Conditional Marketing Approval in Europe in 3Q 2026 Plans to Present Final Results and Subset Analysis of WM Patients from the Phase 2 CLOVER WaM Clinical Study of Iopofosine I 131 Anticipates Dosing of First Patients in Phase 1b Study of CLR 125 for the Treatment of Triple Negative Breast
About this update from Cellectar Biosciences, Inc.
[{"type":"image","alt":"Cellectar Biosciences, Inc.","displaySize":"","headline":null,"caption":"Cellectar Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":296,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/7baccc0d962891d85da2697559b3ccb0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qCQXkIySESVHpCuJXj8EOw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7baccc0d962891d85da2697559b3ccb0","width":296,"height":300}},"lazy":false},{"type":"text","content":"Following Guidance from the European Medicines Agency’s (EMA) Scientific Advice Working Party (SAWP) Regarding Iopofosine I 131 for the Treatment of Waldenstrom’s Macroglobulinemia (WM), Expects to Submit for Conditional Marketing Approval in Europe in 3Q 2026","length":260,"tagName":"p"},{"type":"text","content":"Plans to Present Final Results and Subset Analysis of WM Patients from the Phase 2 CLOVER WaM Clinical Study of Iopofosine I 131","length":128,"tagName":"p"},{"type":"text","content":"Anticipates Dosing of First Patients in Phase 1b Study of CLR 125 for the Treatment of Triple Negative Breast Cancer in 1Q26 with Interim Data Mid-2026","length":151,"tagName":"p"},{"type":"text","content":"FLORHAM PARK, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the development of targeted radiotherapeutics for cancer, today announces plans to highlight the company’s 2026 strategic initiatives at the upcoming Biotech Showcase, taking place January 12-15, 2026, in San Francisco during the 44th Annual JP Morgan Healthcare Conference. James Caruso, president and CEO of Cellectar, will present a corporate update on Tuesday, January 14, 2025, at 1:30 pm Pacific Time.","length":569,"tagName":"p"},{"type":"text","content":"2025 Achievements","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Received feedback from the SAWP supporting a Conditional Marketing Authorization (CMA) filing for iopofosine I 131 in WM based upon our CLOVER WaM study","length":152,"tagName":"p"}]},{"val":[{"type":"text","content":"U.S. Food and Drug Administration (FDA) granted Break Through Designation (BTD) for iopofosine I 131 in relapsed/refractory WM","length":126,"tagName":"p"}]},{"val":[{"ty...